Global private equity and venture capital news and research

Nurix raises $25.1m Series B from Third Rock, The Column Group

22 May 2014

biotech_lrgThird Rock Ventures and The Column Group have invested $25.1m in Series B capital in biotec startup Nurix, which is focused on developing therapies that modulate the ubiquitin proteasome system.

Sorry, to get access to this you need to subscribe for free.

In order to view more content, sign-up to our free daily newsletter.

If you would like to read the premium stories, have complete access to our breaking news and Limited Partner magazine you need to become a Premium Subscriber.

Subscribe to AltAssets today

Login to AltAssets

Legals & Terms of UsePrivacy Policy

AltAssets is registered as a trademark of Investor Networks Limited (06695690).
Registered Office: WeWork 4001, 1 Fore Street, London, EC2Y 5EJ
Content is © AltAssets 2000-2016